eligibility_summary
Adults 18–79 with ECOG 0–1, survival ≥12 wks, stage IIIB–IV NSCLC, failed prior therapy per genotype (driver–: PD‑1/PD‑L1+platinum, EGFR+: failed 1st/2nd gen with T790M– or any failed 3rd gen, other drivers: failed 1L targeted). ≥1 measurable lesion, Trop2 ≥50% weak+, adequate organs, contraception. Exclude: severe infection, uncontrolled brain mets, serious heart disease/ILD/autoimmune, active HBV/HCV/HIV/syphilis, pregnancy, bleeding risk, recent anti‑tumor therapy (<3 wks), recent multiple cancers, drug allergy, investigator judgment.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 1/2, single-arm trial in relapsed/refractory NSCLC testing anti‑Trop2 universal CAR‑NK cells plus chemotherapy. Intervention: Anti‑Trop2 U‑CAR‑NK (allogeneic, gene‑engineered natural killer cell therapy) infused 5 days after chemotherapy. Mechanism: CAR engineered to recognize Trop‑2 (TACSTD2), a transmembrane glycoprotein overexpressed on NSCLC, enabling antigen‑specific NK cell activation and cytotoxicity (perforin/granzyme release, cytokines) against Trop2+ tumor cells. Chemotherapy serves as preconditioning/lymphodepletion to enhance CAR‑NK activity. Targets: Trop2‑expressing tumor cells, pathways include CAR‑mediated NK activation and innate immune cytolysis.